Inclusion Criteria:

          -  Patients must have histologically confirmed relapsed or refractory non-Hodgkin's
             lymphoma or Hodgkin's lymphoma (World Health Organization criteria), for which they
             are unwilling or unable to undergo an autologous stem cell transplant. Patients may
             have relapsed after prior stem cell transplant.

          -  Must have received first line chemotherapy. No upper limit to number of prior
             therapies.

          -  Patients must have measurable disease.

          -  Patients must be age ≥ 18.

          -  Patient has a Karnofsky Performance Status score of ≥70 or Eastern Cooperative
             Oncology Group (ECOG) performance status score of ≤2

          -  The patient or the patient's legal representative is able to understand the risks of
             the study and provide signed informed consent and authorization to use protected
             health information (in accordance with national and local privacy regulations).

          -  Patient has adequate bone marrow reserve, as evidenced by:

               -  Absolute neutrophil count (ANC) of ≥1.0x109/L.

               -  Platelet count of ≥50x109/L.

          -  Patient has adequate renal function, as evidenced by a creatinine within the
             institutional limits of normal or a calculated creatinine clearance of ≥30 mL/min
             according to the Cockcroft-Gault equation.

          -  Patient has adequate hepatic function, as evidenced by serum bilirubin values <2.0
             mg/dL and serum alanine transaminase (ALT) and/or aspartate transaminase (AST) values
             <3 × the upper limit of normal (ULN) of the local laboratory reference range.
             (Patients with isolated elevations in alkaline phosphatase (ALP) <5 × ULN in the
             presence of bony disease are not excluded from participating in the study.)

          -  Females of childbearing potential must have a negative urine or serum pregnancy test
             within 7 days of (C1D1) and have adequate contraception. (A female is considered to be
             not of childbearing potential if she has undergone bilateral oophorectomy or if she
             has been menopausal without a menstrual period for 12 consecutive months.)

        Exclusion Criteria:

          -  Prior Therapy

               1. Patients who have had chemotherapy or radiotherapy within 2 weeks of study drug
                  treatment or those who have not recovered from adverse events due to agents
                  administered

               2. Systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day
                  prednisone during the 7 days prior to the start of the study drugs.

               3. No monoclonal antibody within 3 months unless evidence of disease progression.

          -  Patients may not be receiving any other investigational agents.

          -  Patients with known central nervous system metastases, including lymphomatous
             meningitis

          -  Any known cardiac abnormalities such as:

               -  Congenital long QT syndrome

               -  Corrected QT (QTc) interval ≥ 500 milliseconds;

          -  Uncontrolled inter-current illness

          -  Pregnant or nursing women

          -  Patient is known to be Human Immunodeficiency Virus (HIV)-positive

          -  Active Hepatitis A, Hepatitis B, or Hepatitis C infection

          -  Patient has a history of surgery that would interfere with the administration or
             absorption of the oral study drugs